GZYJPCO(SH:603058) Shang Hai Zheng Quan Bao·2026-02-02 18:49Group 1 - The board of directors of Guizhou Yongji Printing Co., Ltd. approved the second phase of the acquisition of Phytoca Holdings, with the final purchase price set at AUD 38,509,532.35 (approximately RMB 187 million), reflecting an increase of AUD 17,728,049.95 (approximately RMB 86 million) from the initial estimate [24][26]. - The second phase of the acquisition is part of a broader investment strategy aimed at expanding the company's presence in the regulated pharmaceutical market in Australia, enhancing long-term profitability and competitive strength [27][28]. - The first phase of the equity transfer was completed on April 7, 2025, with Yongji Health holding 60% of Phytoca Holdings, which will be included in the company's consolidated financial statements [11][12]. Group 2 - The second phase of the equity purchase price is determined based on a dynamic adjustment formula linked to Phytoca Holdings' audited EBIT for the fiscal year 2025, which was AUD 8,481,083.16 (approximately RMB 41 million) [14][17]. - The company plans to apply for a merger loan of RMB 100 million to finance part of the second phase acquisition, with a loan term of 5 years and an interest rate of 3.8% [20][24]. - The acquisition is expected to optimize the company's financing structure and support its strategic goals, with no significant financial risks anticipated from the merger loan [28].